Celldex Therapeutics, Inc. (NASDAQ:CLDX) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.24 in the quarter versus EPS of $-0.23 in the year-earlier quarter. Revenue Decreased 51.74% to $970,000 from the year-earlier quarter.
Celldex Therapeutics, Inc. reported adjusted EPS loss of $0.24 per share. By that measure, the company missed the mean analyst estimate of $-0.22. It missed the average revenue estimate of $1.67 million.